TP53 Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer We evaluated the efficacy and safety of ...
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. This ...
In a new phase 3, double-blind study, researchers explored the efficacy and safety of combination therapy using subcutaneous (SC) belimumab and rituximab for the treatment of active systemic lupus ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced ...
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
“Can the blind lead the blind? Shall they not both fall into the pit?” Luke 6:39 While “the blind leading the blind” has become an often-used idiom of incompetency and ineffectiveness, the “randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results